Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients
Retrieved on:
Wednesday, August 31, 2022
Mortality, National, COVID-19, Surgery, Research, Technology, Renal replacement therapy, Division, Hospital, Obesity, Survival, CEO, Society of Thoracic Surgeons, Disease, Overload, Critical care, KBT, Journal of Cardiac Surgery, Heart failure, Risk, CAD, U.S. Pharmacist, Pediatrics, Science, CABG, NIH, SEC, Acute kidney injury, Journal, GLOBE, Heart transplantation, Diuretic, CRRT, Hypervolemia, Nasdaq, Company, Hypertension, Adult, Ultrafiltration, Diabetes, Coronary artery disease, Private Securities Litigation Reform Act, Growth, Society, Forward-looking statement, Trial of the century, Patient, Baylor Scott & White Medical Center – Temple, Pharmaceutical industry, Medicine
A total of 254 CABG procedures were performed during this period, and ultrafiltration was used in 17 (6.7%) patients.
Key Points:
- A total of 254 CABG procedures were performed during this period, and ultrafiltration was used in 17 (6.7%) patients.
- Despite an elevated mean Society of Thoracic Surgeons mortality score of 5.7% (range 0.6-50.0), the 30-day survival rate of patients treated with ultrafiltration was 100%.
- The Aquadex System offers a significant opportunity to the medical community to improve clinical outcomes.
- In addition to cardiovascular surgery, Nuwellis continues to make significant progress in other key areas of patient need, including heart failure and pediatrics.